

1 **Article Summary Line:** COVID-19 antibodies were measured in saliva and 20% of vaccinated  
2 subjects experienced a 90% drop in peak antibody levels over the course of monitoring.

3 **Running Title:** COVID-19 vaccine antibody kinetics in saliva

4 **Keywords:** Kinetics; Antibody; COVID-19; SARS-CoV-2; Saliva; Diagnostics; Monitoring;  
5 List of keywords. There is no limit on the number of keywords. Use terms listed in the Medical  
6 Subject Headings from Index Medicus.

7 **Title:** The Kinetics of COVID-19 Vaccine Response in a Community Vaccinated Population

8 **Authors:**

9 Michael Tu, PhD<sup>1</sup>; Samantha Chiang, DDS<sup>2</sup>; Richard Bender, MD<sup>1</sup>; David T.W. Wong, DMD,  
10 DMSc<sup>2</sup> ; Charles Strom MD, PhD<sup>1\*</sup>.

11

12 **Affiliations:**

13 <sup>1</sup> Liquid Diagnostics LLC, San Clemente, CA, USA (Tu, M.; Bender, R; Strom, C)

14 <sup>2</sup> UCLA School of Dentistry, Los Angeles, CA, USA (Chiang, S; Wong, D)

15 \* Corresponding Author.

16

17

18

19

20 **Abstract—word count (150 words max)**

21 We used a noninvasive electrochemical quantitative assay for IgG antibodies to SARS-  
22 CoV-2 S1 in saliva to investigate the kinetics of antibody response in a community-based  
23 population who had received either the Pfizer or Moderna mRNA-based vaccines. Samples were  
24 received from a total of 97 individuals including a subset of 42 individuals who collected  
25 samples twice-weekly for 3 months or longer. In all, 840 samples were collected and analyzed.  
26 In all individuals, salivary antibody levels rose sharply in the 2-week period following their  
27 second vaccination, with peak antibody levels being at 10-20 days post-vaccination. We  
28 observed that 20%, 10% and 2.4% of individuals providing serial samples had a 90%, 95%, and  
29 99% drop respectively from peak levels during the duration of monitoring and two patients fell  
30 to pre-vaccination levels (5%). The use of non-invasive quantitative salivary antibody  
31 measurement can allow widespread, cost-effective monitoring of vaccine response.

32

33

34

## INTRODUCTION

35           The pandemic caused by SARS-CoV-2 has led to worldwide fatalities and social and  
36 economic disruption. In the autumn of 2020, the FDA issued emergency use authorization for  
37 two mRNA-based vaccines manufactured by Pfizer/BioNTech COMIRNATY® (Pfizer) or  
38 Moderna/NIAID (Moderna). Both vaccines use mRNA sequences from the S1 domain of the  
39 SARS-CoV-2 Spike Protein (*1-5*), and vaccines require two doses given 21 or 28 days apart in  
40 order to achieve 95% protection against SARS-CoV-2 infection (*1-5*). It is unclear whether all  
41 individuals developed antibodies with 5% at risk of breakthrough infection, or whether a modest  
42 fraction of individuals will not respond develop antibodies and remain at risk of infections.

43           Unlike the predicted statistics for the healthy general population, it is known that patients  
44 on immunosuppressive drugs and cancer patients may not develop a robust antibody response to  
45 vaccine administration (*7*). It is possible that a fraction of individuals in the population may have  
46 an undetected immune deficiency that prevents them from responding appropriately to the  
47 standard vaccine regimen. Consequently, the Centers for Disease Control and Prevention (CDC)  
48 is currently recommending booster immunizations be deployed beginning in the fall of 2021(*8*).

49           Several studies have demonstrated that circulating antibody levels decrease over time  
50 following either vaccination or infection (*9-14*). Breakthrough infections are being observed in  
51 fully vaccinated individuals. It is not known what level, if any, of circulating antibody is  
52 required to have immunoprotection against COVID-19 infection. Current publications report  
53 very little information regarding the kinetics of antibody levels in patients following vaccination  
54 and these studies only report antibody levels at 5.5 weeks and 90 day intervals post second  
55 vaccination respectively (*15,16*). Current research is underway to determine whether the efficacy  
56 of booster immunization doses and its timing in protecting against SARS-CoV-2 infection,

57 especially in light of the emergence of highly contagious variants such as the delta variant that  
58 may be less sensitive to the current vaccines.

59 It is clear that most, if not all, individuals receiving both doses of either the Pfizer or  
60 Moderna vaccine respond with a robust IgG response (1-5). However, what is lacking, is  
61 frequent kinetic monitoring and long-term monitoring of antibody levels in a community  
62 vaccinated population. Non-invasive monitoring using saliva allows for frequent and long-term  
63 monitoring of vaccinated individuals and entire populations.

64 We have developed a saliva-based quantitative assay for IgG antibodies to the S1 domain  
65 of Spike protein in SARS-CoV-2 using a novel electrochemical platform formerly known as  
66 EFIRM® and now called Amperial® (17). Previously, we used this assay to monitor patients  
67 who had recovered from COVID-19. This assay was greater than 98% specific for individuals  
68 with prior COVID-19 infections and gave proportional results to serum assays performed at the  
69 same time on the same patient. Two other groups have similarly demonstrated the ability of  
70 saliva to be a surrogate for serum or plasma measurement of SARS-CoV-2 antibodies (18,19).

## 71 **METHOD**

### 72 **SARS-CoV-2 Salivary Assay Equipment**

73 The Amperial® platform uses a proprietary 96-well microtiter plate containing gold  
74 electrodes at the bottom of each well and an electrochemical reader system (EZLife Bio Inc, Los  
75 Angeles, CA). The description of the Elzie Amperial® COVID-19 Antibody assay and the assay  
76 performance and validation have been described previously (17) and is summarized in the  
77 following section.

## 78 **Immobilization of SARS-CoV-2 on Plate Surface**

79 For the preparation of the antigen coated wells we prepare a 10 µg/mL SARS-CoV-2 S1  
80 antigen (SinoBiological US Inc, Wayne, PA) diluted in a solution of 72.25 mM pyrrole (Sigma-  
81 Aldrich, St. Louis, MO) and 0.147M KCl mixture. This antigen-polymer mixture was then  
82 briefly vortexed for 1 sec and then 30 µL was added to each well. Each plate contains wells  
83 containing antigen alternated with wells containing polymer without antigen added. The plate  
84 was then inserted into the electrochemical plate device and a square wave potential applied that  
85 consists of 1 second of +350 mV and 1 second for +1100mV for 4 cycles (8 seconds total) to  
86 electropolymerize the polymer and antigen-polymer on the surface. After the electrochemical  
87 polymerization, each electrode was washed for 3 cycles in a buffer of 1x phosphate-buffered  
88 saline (PBS, Affymetrix, USA) and 0.05% Tween 20 (BioRad, USA), referred to as PBS-T.

## 89 **Sample Preparation and Incubation**

90 Saliva samples were diluted 1:10 in a 1% (w/v) Casein/PBS solution (ThermoFisher,  
91 Waltham, MA). Internal standards consist of SARS-CoV-2 IgG antibodies (Absolute Antibody,  
92 Oxford, United Kingdom) diluted in 1% (w/v) Casein/PBS solution at varying concentrations in  
93 the linear range of the assay to provide a standard curve. Thirty microliters of the samples and  
94 standard are then added to their respective wells in the coated electrode plate. All patient samples  
95 were added to both a pyrrole only well and an S1 antigen coated well. The plate is incubated at  
96 room temperature for 10 min before washing with PBS-T.

## 97 **Secondary Antibody and Reporter Enzyme**

98 Subsequently biotinylated Goat Anti-Human IgG Fc (ThermoFisher, Waltham, MA) was  
99 diluted 1:500 in 1% (w/v) Casein/PBS solution and 30  $\mu$ L added to the well. The plate was then  
100 incubated for 10 min at room temperature before a PBS-T wash.

101 Following the removal of the secondary antibody, a Poly80 Horseradish peroxidase  
102 enzyme is prepared at 1:5 dilution ratio in 1% (w/v) Casein/PBS solution and incubated at 10  
103 minutes at room temperature prior to another PBS-T wash.

## 104 **Measurement of Electrochemical Signal and Data Analysis**

105 Sixty microliters of 1 Step Ultra-TMB (ThermoFisher, Waltham, MA) is added to the  
106 wells and the plate immediately inserted into the electrochemical reader device, with a fixed  
107 potential of -200 mV and simultaneous measurement of electrochemical current for all 96 wells  
108 is measured 2 separate times over a 60 second period.

109 Signal of the last 10 seconds of the readout procedure is averaged for final quantitative  
110 signal value. All saliva samples tested were normalized by subtracting the signal of the polymer  
111 only wells with the antigen-polymer coated wells. Standards were also compared to calibrators  
112 for quantification.

## 113 **Human Subjects**

114 Research protocol and consents were approved by the Western Internal Review Board  
115 (Study #1302611, Expiration Date: March 19<sup>th</sup>, 2022).

116 Individuals under the age of 18 years and individuals receiving immunosuppressive drugs or  
117 cancer chemotherapy were excluded from the study.

118 Volunteers who had previously received a Pfizer (BioNTech), Moderna, or Johnson and  
119 Johnson Vaccine for SARS-CoV-2 were consented. Subjects were issued a questionnaire  
120 collecting information about vaccination dates and vaccine type, along with questions to  
121 eliminate subjects who were immunocompromised or taking immunosuppressants.

122 The study comprised of a longitudinal and a cross-sectional study cohort. For the  
123 longitudinal study cohort, a cohort receiving either the Pfizer (n=15) or Moderna (n=27) mRNA  
124 vaccine were monitored with a first-morning twice-weekly collection. Collections lasted for as  
125 long 8 months post vaccination for some individuals. We analyzed saliva at a single time point  
126 for another 31 and 24 individuals receiving the Pfizer and Moderna vaccines respectively. This  
127 has allowed us to make several conclusions regarding the kinetics of COVID-19 vaccine  
128 response in community vaccinated populations. In all more than 840 samples have been collected  
129 and analyzed.

### 130 **Sample Processing Device and Protocol**

131 Saliva samples were collected using the Orasure® Oral Fluid Collection Device (Orasure  
132 Technologies, Bethlehem, PA), which consists of an absorbent pad on the end of a long wand  
133 and a collection tube with preservative solution. Subjects insert the absorbent pad in the mouth  
134 for a minimum of 2 minutes in order to absorb adequate saliva fluids. The absorbent pad is then  
135 immersed into a collection tube and the wand broken at a scored breakpoint to allow the device  
136 to be securely capped. Individuals participating in longitudinal studies placed the capped  
137 collectors in a zip lock bag and then into their home freezer until shipping them to the laboratory  
138 at ambient temperature. Individuals providing single samples kept the samples at room  
139 temperature until shipping to the laboratory.



162 As can be seen in Fig 1, however, 2 individuals responded with a maximum level of 50  
163 ng / ml. Individual 3 in the Pfizer group had a peak response of approximately 50 ng / ml and  
164 then stabilized at approximately 25 ng / ml. Individual 3 in the Moderna group had a short-  
165 duration peak of 50 ng /ml followed by a return to baseline 30 days post second vaccination. All  
166 but 2 patients experienced a gradual, but steady decline in antibody levels. These decreasing  
167 levels may correlate with the need for booster vaccinations.

168 Clinical trials data revealed an approximate 50% protection for individuals 2 weeks after  
169 having received their first immunization with either the Modern or Pfizer vaccine (1-5). We  
170 wondered whether this could be a function of antibody response in vaccinated patients. Of the 42  
171 subjects that were serially monitored, 36 supplied samples before the second dose. In the subjects  
172 that were collected prior to the second dose, 88% of the Moderna subjects had detectable  
173 antibodies prior to the second dose and 50% of the Pfizer subjects had detectable antibodies prior  
174 to the second dose (see Table 2).

### 175 **Summary Statistics for Kinetic Studies**

176 Table 1 shows the summary statistics for the volunteers participating in the kinetic  
177 studies. The average time to maximum antibody level was 22 days for Moderna and 30 days for  
178 Pfizer. The maximum levels were nearly identical for the 2 vaccines with Moderna vaccinated  
179 individuals having average peak levels of 127 ng / ml and 130 ng /ml respectively for Moderna  
180 vaccinated and Pfizer vaccinated individuals. These levels are similar to those we observed in  
181 convalescent hospitalized COVID-19 patients and 5 fold higher than more mildly symptomatic  
182 individuals (17).

183 In addition to the 42 volunteers participating in the kinetic studies we had an additional  
184 53 individuals submitted single samples for this study. Figure 2 is a summary of all the data

185 representing 840 individual time points including the multiple time points for the 42 volunteers  
186 submitting multiple samples and the 53 volunteers submitting only one samples. The samples are  
187 normalized to days after receiving the second vaccine dose.

188 Figure 2 is a summary of these data showing a box plot of weekly antibody levels for  
189 individuals both pre and post second vaccination. The trend is clear. Robust antibody levels are  
190 present for the initial 60 days following the second vaccination. Subsequently, levels begin  
191 falling gradually, but consistently. The data demonstrate a steady decrease in antibody levels  
192 with increasing time following vaccination.

### 193 **Summary of subjects with significant drops from peak value**

194 Table 3 is a summary of volunteers who have experienced drops of more than 90%, 95%,  
195 and 99% from their peak values grouped by vaccine type. Although a higher percentage of Pfizer  
196 vaccinated patients experience a decrease of 90% or more (33% vs 15%) and 95% or more (13%  
197 v 8%) no Pfizer volunteers experienced a 99% drop whereas one Moderna vaccinated patient  
198 experienced a 99% drop in antibody levels (see Table 3). The numbers are not sufficient to form  
199 any conclusions regarding any potential differences between the 2 vaccines but do show that,  
200 with time, antibody levels drop to 90% of their peak level in 20% of community vaccinated  
201 individuals.

202 Figure 3 are the kinetic plots of the 9 vaccinated individuals who experienced >90%  
203 drops in antibody levels following vaccination. It is apparent that that there is no correlation with  
204 the original peak value with prediction of eventual 90% drop in antibody level. Two individuals  
205 had peak levels above 200 ng / ml indicating a robust initial response. There were two volunteers  
206 who had initial peak values of only 50 ng / ml who also dropped to low levels. Two individuals  
207 (5%) dropped to undetectable levels; one a Pfizer patient and one a Moderna patient.

## 208 **Case Study: Prednisone Effects**

209           A male patient in their sixties was given a 3 week course of prednisone (50 mg / day for  
210 14 days followed by a week of tapering) for a nasal polyp approximately 2 months after his  
211 second dose of vaccine. The kinetics of his antibody production is shown in Figure 4 with the  
212 time period that the prednisone was being administered is highlighted in grey. As can be seen,  
213 antibody levels began falling with the onset of treatment to baseline levels and remained  
214 suppressed for several weeks following the taper. However, antibody levels did rebound and then  
215 began to slowly decline thereafter.

## 216 **Evaluation of Delta Variant Antigen to Salivary Antibodies**

217           The Delta variant of SARS-CoV-2 has become the predominant variant in the United  
218 States. We therefore investigated whether antibodies present in convalescent and vaccinated  
219 patients are capable of recognizing the S1 antigen of the Delta variant. We designed an  
220 Amperial® assay substituting monoclonal S1 delta variant antigen for the wild type S1 antigen  
221 (see Methods). The standard curves for this assay compared to the wild type antigen assay are  
222 shown in Figure 5A and demonstrate very similar assay characteristics. There is some indication  
223 of slightly reduced binding efficiency for monoclonal Anti-S1 antibodies to the Delta variant  
224 versus the wild type S1 antigen but these differences are not enough to alter testing results.

225           Next, we investigated whether antibodies present in convalescent individuals and  
226 vaccinated individuals could recognize and bind to the Delta variant S1 antigen. A total of 3 pre  
227 2019 samples were used as controls, with also 1 immunodeficient organ transplant patient run for  
228 reference. Three samples from convalescent patients with detectable antibody levels were used.  
229 These patients were infected before the delta variant emerged. In addition, 3 Pfizer and 4



253 Herd immunity from widespread community vaccination is a key component in  
254 preventing COVID-19 infections and in curbing the pandemic. Several questions remain  
255 unanswered. Our data can help provide the answers to some of these questions:

256 Does everyone respond to vaccination with a robust immune response? In this study all  
257 vaccinated individuals did respond, although some with much lower antibody levels than the  
258 average. Antibody monitoring post vaccination could identify the individuals who did not react  
259 to vaccination with a robust antibody response and allow these individuals to have an  
260 immunologic evaluation or an additional injection or a different vaccine type.

261 Will booster vaccination be necessary? Recent data regarding breakthrough infections  
262 and CDC recommendations are for immunocompromised individual and patients receiving  
263 immunosuppressive therapy should receive a third dose of the vaccine regardless of timing.  
264 Health care workers and high-risk individuals are scheduled to receive boosters in September.  
265 Our data supports this approach in that most individuals experience a continuous drop in  
266 antibody levels with time and 5% of individuals dropped to undetectable levels. Although it is  
267 not clear what level of antibody, if any, is necessary to prevent COVID-19 infection, individuals  
268 with baseline levels of antibodies may be at higher risk to acquire infection.

269 Will a fourth vaccination be needed? Future kinetic studies will be necessary to  
270 determine if antibody levels will remain stable following a third vaccination. Noninvasive  
271 monitoring using saliva home collection provides a low cost, effective way to perform  
272 population monitoring of vaccine levels following a third vaccination.

273 Will the current vaccines protect against the Delta variant? Our data shows that  
274 antibodies produced in convalescent patients or mRNA vaccinated subjects do recognize the

275 Delta variant. Although this cannot insure an equal protection level against serious infection it is  
276 reassuring.

277        Could any individuals in low-risk groups benefit from booster vaccination? Our data  
278 suggests that about 20% of individuals experience a fall of >90% of antibody levels 3 months  
279 following completion of their vaccination protocol. These individuals might benefit from early  
280 booster shots to prevent breakthrough infections. If an individual with a low antibody level is  
281 identified by saliva testing, further evaluation can be performed using serum titers to confirm the  
282 initial observation.

283        We should stress that it has not been determined what level of circulating IgG antibody, if  
284 any, is necessary to prevent COVID infection. The data in this article must be interpreted in that  
285 light. The ability to noninvasively and cost efficiently quantitates COVID-19 antibody levels  
286 could be an important tool in investigating the relationship between circulating antibodies to  
287 immunity.

288        The results presented in this work regarding the salivary monitoring of SARS-CoV-2 are  
289 congruent with recommendations given by the USA CDC and established literature regarding  
290 SARS-CoV-2 antibody in vaccinated populations. While there still remains a need for a more  
291 comprehensive evaluation of the relationship between salivary SARS-CoV-2 antibodies and  
292 those present in the blood, our work demonstrates that our noninvasive quantitative saliva assay  
293 could be valuable for evaluating a community vaccinated population and to further investigate  
294 the relationship between circulating antibody to COVID-19 immunity.

295

296 **Acknowledgments**

297 The authors wish to thank our volunteers who participated in the study. Funding sources: U18  
298 TR003778, U54 HL119893 (to DTWW)

299 **Disclaimers**

300 D. Wong is consultant to Colgate-Palmolive, Mars Wrigley and GSK. D. Wong also have  
301 equity in Liquid Diagnostics and RNameTRIX. DW, CS, MT, RB are shareholders in Liquid  
302 Diagnostics LLC. MT is a paid consultant of Liquid Diagnostics LLC. RB is a consultant to  
303 Amgen, Bristol Myers Squibb.

304 **Author Bio** (first author only, unless there are only 2 authors)

305 Michael Tu, PhD is the Chief Scientific Officer of Liquid Diagnostics LLC. His training  
306 and background in biomedical engineering and biosensors, and his work primarily emphasizes  
307 the development of novel diagnostic tools for disease related biomarkers.

308

309 **References**

310 1: Jackson LA, Anderson EJ, Roupael NG, Roberts PC, Makhene M, Coler RN, et al.; mRNA-  
311 1273 Study Group. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. *N Engl J*  
312 *Med.* 2020 Nov 12;383(20):1920-1931. doi: 10.1056/NEJMoa2022483. Epub 2020 Jul 14.

313 PMID: 32663912; PMCID: PMC7377258.

314 2: Barrett JR, Belij-Rammerstorfer S, Dold C, Ewer KJ, Folegatti PM, Gilbride C, et al. Oxford  
315 COVID Vaccine Trial Group. Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with  
316 a booster dose induces multifunctional antibody responses. *Nat Med.* 2021 Feb;27(2):279-288.

317 doi: 10.1038/s41591-020-01179-4. Epub 2020 Dec 17. Erratum in: *Nat Med.* 2021

318 Jun;27(6):1113. PMID: 33335322.

319

320 3: Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, et al. COVID-19  
321 vaccine BNT162b1 elicits human antibody and T<sub>H</sub>1 T cell responses. *Nature.* 2020

322 Oct;586(7830):594-599. doi: 10.1038/s41586-020-2814-7. Epub 2020 Sep 30. Erratum in:

323 *Nature.* 2021 Feb;590(7844):E17. PMID: 32998157.

324 4: Wang Z, Schmidt F, Weisblum Y, Muecksch F, Barnes CO, Finkin S, et al.. mRNA vaccine-  
325 elicited antibodies to SARS-CoV-2 and circulating variants. *Nature.* 2021 Apr;592(7855):616-

326 622. doi: 10.1038/s41586-021-03324-6. Epub 2021 Feb 10. PMID: 33567448.

327 5: Ella R, Vadrevu KM, Jogdand H, Prasad S, Reddy S, Sarangi V, et al. Safety and

328 immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised,  
329 phase 1 trial. *Lancet Infect Dis.* 2021 May;21(5):637-646. doi: 10.1016/S1473-3099(20)30942-7.

330 Epub 2021 Jan 21. Erratum in: *Lancet Infect Dis.* 2021 Apr;21(4):e81. PMID: 33485468;

331 PMCID: PMC7825810.

- 332 6: Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, et al. Immunogenicity and safety of a  
333 recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or  
334 older: a randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet*. 2020 Aug  
335 15;396(10249):479-488. doi: 10.1016/S0140-6736(20)31605-6. Epub 2020 Jul 20. PMID:  
336 32702299; PMCID: PMC7836858.
- 337 7: Patten P, Di Rosa F, Papa S, Tree T, Doores KJ, Hayday AC, et al. Safety and  
338 immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with  
339 cancer: interim analysis of a prospective observational study. *Lancet Oncol*. 2021 Jun;22(6):765-  
340 778. doi: 10.1016/S1470-2045(21)00213-8. Epub 2021 Apr 27. PMID: 33930323; PMCID:  
341 PMC8078907.
- 342 8: <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/booster-shot.html>  
343 Accessed 9/11/2021
- 344 9: Xiang T, Liang B, Fang Y, Lu S, Li S, Wang H, et al. Declining Levels of Neutralizing  
345 Antibodies Against SARS-CoV-2 in Convalescent COVID-19 Patients One Year Post Symptom  
346 Onset. *Front Immunol*. 2021 Jun 16;12:708523. doi: 10.3389/fimmu.2021.708523. PMID:  
347 34220870; PMCID: PMC8242354.
- 348 10: Robbiani DF, Gaebler C, Muecksch F, Lorenzi JCC, Wang Z, Cho A, et al. Convergent  
349 antibody responses to SARS-CoV-2 in convalescent individuals. *Nature*. 2020  
350 Aug;584(7821):437-442. doi: 10.1038/s41586-020-2456-9. Epub 2020 Jun 18. PMID:  
351 32555388; PMCID: PMC7442695.
- 352 11: Ni L, Ye F, Cheng ML, Feng Y, Deng YQ, Zhao H, et al. Detection of SARS-CoV-2-  
353 Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals. *Immunity*.

- 354 2020 Jun 16;52(6):971-977.e3. doi: 10.1016/j.immuni.2020.04.023. Epub 2020 May 3. PMID:  
355 32413330; PMCID: PMC7196424.
- 356 12: Rodda LB, Netland J, Shehata L, Pruner KB, Morawski PA, Thouvenel CD, et al. Functional  
357 SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19. *Cell*. 2021 Jan  
358 7;184(1):169-183.e17. doi: 10.1016/j.cell.2020.11.029. Epub 2020 Nov 23. PMID: 33296701;  
359 PMCID: PMC7682481.
- 360 13: Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody Responses to SARS-CoV-2  
361 in Patients With Novel Coronavirus Disease 2019. *Clin Infect Dis*. 2020 Nov 19;71(16):2027-  
362 2034. doi: 10.1093/cid/ciaa344. PMID: 32221519; PMCID: PMC7184337.
- 363
- 364 14: Li K, Huang B, Wu M, Zhong A, Li L, Cai Y, et al. Dynamic changes in anti-SARS-CoV-2  
365 antibodies during SARS-CoV-2 infection and recovery from COVID-19. *Nat Commun*. 2020  
366 Nov 27;11(1):6044. doi: 10.1038/s41467-020-19943-y. PMID: 33247152; PMCID:  
367 PMC7699636.
- 368 15: Eliakim-Raz N, Massarweh A, Stemmer A, Stemmer SM. Durability of Response to SARS-  
369 CoV-2 BNT162b2 Vaccination in Patients on Active Anticancer Treatment. *JAMA*  
370 *Oncol*. Published online August 11, 2021. doi:10.1001/jamaoncol.2021.4390
- 371 16: Widge AT, Roupael NG, Jackson LA, Anderson EJ, Roberts PC, Makhene M, et al.  
372 mRNA-1273 Study Group. Durability of Responses after SARS-CoV-2 mRNA-1273  
373 Vaccination. *N Engl J Med*. 2021 Jan 7;384(1):80-82. doi: 10.1056/NEJMc2032195. Epub 2020  
374 Dec 3. PMID: 33270381; PMCID: PMC7727324.

375 17: Chiang SH, Tu M, Cheng J, Wei F, Li F, Chia D, et al. (2021) Development and validation of  
376 a quantitative, non-invasive, highly sensitive and specific, electrochemical assay for anti-SARS-  
377 CoV-2 IgG antibodies in saliva. PLoS ONE 16(7):e0251342.

378 18: Pisanic N, Randad PR, Kruczynski K, Manabe YC, Thomas DL, Pekosz A et al. COVID-19  
379 Serology at Population Scale: SARS-CoV-2-Specific Antibody Responses in Saliva. J Clin  
380 Microbiol. 2020 Dec 17;59(1):e02204-20. doi: 10.1128/JCM.02204-20. PMID: 33067270;  
381 PMCID: PMC7771435.

382 19: Isho B, Abe KT, Zuo M, Jamal AJ, Rathod B, Wang JH, et al.. Persistence of serum and  
383 saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. Sci Immunol.  
384 2020 Oct 8;5(52):eabe5511. doi: 10.1126/sciimmunol.abe5511. PMID: 33033173; PMCID:  
385 PMC8050884

386

387 Table 1: Summary Statistics for kinetic studies on vaccinated volunteers

	<b>Moderna</b>	<b>Pfizer</b>	<b>Combined</b>
Total Subjects for Longitudinal Study	27	15	42
Average Time Post 2nd Dose to Max Ab	22 days	30 days	24 days
Average Maximum Antibody Level	127 ng / ml	124 ng / ml	126 ng / ml

388

389

390

391

392

393 Table 2. Summary of subjects with measurable antibodies prior to completion of second dose

	<b>Moderna</b>	<b>Pfizer</b>	<b>Combined</b>
Individuals With Data Collected Prior to 2nd Dose	26	10	36
Antibody Produced Before 2nd Dose	23 (88%)	5 (50%)	28 (77%)

394

395


396 Table 3: Individuals with large drops in antibody levels

	<b>Moderna</b>	<b>Pfizer</b>	<b>Combined</b>
Subjects with $\geq 90\%$ drop	15% (4/27)	33% (5/15)	19% (8/42)
Subjects with $\geq 95\%$ drop	8% (2/27)	13% (2/15)	10% (4/42)
Subjects with $\geq 99\%$ drop	4 % (1/27)	0% (0/15)	2.4% (1/42)

397


398

399 Figure 1. Representative Individual Kinetic Experiments: Pfizer and Moderna, with graphs  
400 centered around time 0 being the day of the second vaccination.



404

405 Figure 2. Samples collected from volunteer subjects (n=99) at different time intervals for Pfizer  
406 (n=47) and Moderna (n=52) vaccines were tested and binned to different time intervals relative  
407 to completion of second dose of mRNA vaccine.




408

409

410


411 Figure 3. Plot of individuals measured with over 90% drop from peak.



412


413

414 Figure 4. Case Study Plot of Pfizer vaccinated individual who was administered prednisone  
415 following his vaccination. Shaded area of grey indicates the period of time where prednisone was  
416 taken.




417

418 Figure 5A: Standard curves for both the Wild type and Delta Variant S1 antigens







420 Figure 5B: Comparison of Wildtype Anti SARS-CoV-2 IgG S1 and B.1.6.617.2 variant S1

421 SARS-CoV-2 antigen








# Moderna



Days Relative to Completion of Vaccination (2nd Dose = 0)

# Pfizer



Days Relative to Completion of Vaccination (2nd Dose = 0)

